These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24201160)

  • 1. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation.
    Caselli D; Rosati A; Faraci M; Podda M; Ripaldi M; Longoni D; Cesaro S; Lo Nigro L; Paolicchi O; Maximova N; Menconi MC; Ziino O; Cicalese MP; Santarone S; Nesi F; Aricò M; Locatelli F; Prete A;
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):282-5. PubMed ID: 24201160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
    Chan KW; Mullen CA; Worth LL; Choroszy M; Koontz S; Tran H; Slopis J
    Bone Marrow Transplant; 2002 Jun; 29(12):963-5. PubMed ID: 12098063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.
    Kerl K; Diestelhorst C; Bartelink I; Boelens J; Trame MN; Boos J; Hempel G
    Pediatr Blood Cancer; 2014 Feb; 61(2):306-11. PubMed ID: 24174393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
    Soni S; Skeens M; Termuhlen AM; Bajwa RP; Gross TG; Pai V
    Pediatr Blood Cancer; 2012 Oct; 59(4):762-4. PubMed ID: 22378696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia.
    Kato M; Takahashi Y; Tomizawa D; Okamoto Y; Inagaki J; Koh K; Ogawa A; Okada K; Cho Y; Takita J; Goto H; Sakamaki H; Yabe H; Kawa K; Suzuki R; Kudo K; Kato K
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1690-4. PubMed ID: 24071595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
    Ruiz-Argüelles GJ; Gomez-Almaguer D; Steensma DP
    Am J Hematol; 2012 Sep; 87(9):941. PubMed ID: 22674687
    [No Abstract]   [Full Text] [Related]  

  • 10. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
    Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
    Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.
    Leon-Rodriguez E; Rivera-Franco MM
    Int J Hematol; 2016 Dec; 104(6):644-646. PubMed ID: 27722893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood.
    Bakker B; Oostdijk W; Bresters D; Walenkamp MJ; Vossen JM; Wit JM
    Bone Marrow Transplant; 2004 May; 33(10):1049-56. PubMed ID: 15048143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
    Hamidieh AA; Hamedani R; Hadjibabaie M; Amini M; Sadrai S; Ghavamzadeh A
    Pediatr Hematol Oncol; 2010 Oct; 27(7):529-33. PubMed ID: 20677921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.
    Granados E; de La Cámara R; Madero L; Díaz MA; Martín-Regueira P; Steegmann JL; Arranz R; Figuera A; Fernández-Rañada JM
    Haematologica; 2000 Oct; 85(10):1060-7. PubMed ID: 11025598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.
    Bunin N; Aplenc R; Kamani N; Shaw K; Cnaan A; Simms S
    Bone Marrow Transplant; 2003 Sep; 32(6):543-8. PubMed ID: 12953124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.
    Uppugunduri CR; Rezgui MA; Diaz PH; Tyagi AK; Rousseau J; Daali Y; Duval M; Bittencourt H; Krajinovic M; Ansari M
    Pharmacogenomics J; 2014 Jun; 14(3):263-71. PubMed ID: 24165757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
    Sisler IY; Koehler E; Koyama T; Domm JA; Ryan R; Levine JE; Pulsipher MA; Haut PR; Schultz KR; Taylor DS; Frangoul HA
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M; Jacobsohn D; Duerst R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
    Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringdén O; Hassan M
    Bone Marrow Transplant; 2008 Apr; 41(7):621-5. PubMed ID: 18084338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.